UCB SA (OTCMKTS:UCBJF) Short Interest Up 20.8% in March

UCB SA (OTCMKTS:UCBJF - Get Free Report) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 481,000 shares, a growth of 20.8% from the February 28th total of 398,200 shares. Based on an average daily trading volume, of 3,100 shares, the short-interest ratio is currently 155.2 days. Currently, 0.3% of the company's shares are sold short.

UCB Stock Down 2.5 %

Shares of UCBJF traded down $4.30 during trading hours on Friday, reaching $170.00. The stock had a trading volume of 25 shares, compared to its average volume of 704. UCB has a 52 week low of $123.00 and a 52 week high of $209.66. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The firm has a 50-day moving average of $189.90 and a 200 day moving average of $186.28.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.